Drug Trial Radar · NCT05400330
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Actual
Start
May 8, 2023
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Lexeo TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (and other biomarkers that may be informative for this therapeutic approach). Other secondary objectives include instruments to assess cognitive and clinical AD and to evaluate if treatment with AAVrh.10hAPOE2 improves brain tau pathology with tau PET scan (LX1001-01 Cohorts 3 and 4 only).
Conditions
- Alzheimer Disease
Interventions
LX1001Biological
Gene therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse eventsTime frame: 260 weeks
- Incidence of serious adverse eventsTime frame: 260 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
PPD- Orlando Research Unit
Orlando, Florida
Duke University
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.